StockData

Burning Rock Biotech vs Guardant Health

BNR and GH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and GH compare

Guardant Health grew revenue faster over the last twelve months (42.7% versus 4.6% for Burning Rock Biotech).

Burning Rock Biotech keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −38.3% at Guardant Health.

Guardant Health scores higher on the StockData Score (10 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRGH
Size and price
Market cap–$19.2B
Share price$12.50$143.28
Change, 1 year6.5%51.8%
Change, 5 years−90.9%34.0%
Beta (5Y)2.521.34
Employees6672,506
StockData Score
Total score410 (better)
Valuation score00
Growth score14 (better)
Performance score11
Health score25 (better)
Dividend score00
Valuation
P/S–16.3×
FCF yield–−1.3%
Growth
Revenue growth (TTM)4.6%42.7% (better)
Revenue growth, 5Y average4.6%27.9% (better)
Profitability
Gross margin74.7% (better)65.0%
Operating margin−10.2% (better)−39.7%
Net margin−10.3% (better)−38.3%
FCF margin−6.2% (better)−20.3%
Return on equity−9.9%–
Return on invested capital−72.5%–
Financial health
Debt / equity0.00–
Interest coverage–−97.6×
Current ratio2.994.03 (better)
Altman Z-score–3.49
Piotroski F-score56 (better)
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield–0.00%
Ownership
Held by institutions1.8%99.8%
Held by insiders19.0%1.8%
Insider net buying, 12 months$11.6M (better)−$173M
Short interest, % of float–7.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.